August 28, 2020

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A retrospective propensity-matched observational study (n=878) found that famotidine, a histamine-2 blocker used to treat acid reflux and ulcers, was associated with a decreased risk of in-hospital mortality (OR=0.4, 95% CI: 0.2-0.96) as well as combined outcome of death or intubation (OR=0.5, 95% CI: 0.2-0.96). While patients treated with famotidine were younger (63.5 +/- 15 vs 67.5 +/- 15.8), propensity score matching to adjust for age did not change the associations. Forty-eight of 83 (58%) patients in the famotidine group received corticosteroids versus 329/689 (48%) of patients in the non-famotidine group.

Mather et al. (Aug 26, 2020). Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19. American Journal of Gastroenterology. https://journals.lww.com/ajg/Documents/AJG-20-2074_R1.pdf